GO-DACT : a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10451/45110 |
Resumo: | © author(s) (or their employer(s)) 2020. Re-use permitted under CC BY- nC. no commercial re-use. see rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license. |
id |
RCAP_5d121c3e286972474cf1bc71aaf0edeb |
---|---|
oai_identifier_str |
oai:repositorio.ul.pt:10451/45110 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
GO-DACT : a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritisAnti-TNFMethotrexateOutcomes researchPsoriatic arthritis© author(s) (or their employer(s)) 2020. Re-use permitted under CC BY- nC. no commercial re-use. see rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license.Objectives: To assess the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy in psoriatic arthritis (PsA) dactylitis. Methods: Multicentre, investigator-initiated, randomised, double-blind, placebo-controlled, parallel-design phase 3b trial in 11 Portuguese rheumatology centres. Patients with PsA along with active dactylitis and naive to MTX and biologic disease-modifying antirheumatic drugs (bDMARDs) were randomly assigned to golimumab or placebo, both in combination with MTX. The primary endpoint was Dactylitis Severity Score (DSS) change from baseline to week 24. Key secondary endpoints included DSS and Leeds Dactylitis Index (LDI) response, and changes from baseline in the LDI and MRI dactylitis score. Analysis was by intention-to-treat for the primary endpoint. Results: Twenty-one patients received golimumab plus MTX and 23 MTX monotherapy for 24 weeks. One patient from each arm discontinued. Patient inclusion was halted at 50% planned recruitment due to a favourable interim analysis. Median baseline DSS was 6 in both arms. By week 24, patients treated with golimumab plus MTX exhibited significantly greater improvements in DSS relative to MTX monotherapy (median change of 5 vs 2 points, respectively; p=0.026). In the golimumab plus MTX arm, significantly higher proportions of patients achieved at least 50% or 70% improvement in DSS and 20%, 50% or 70% improvement in LDI in comparison to MTX monotherapy. Conclusions: The combination of golimumab and MTX as first-line bDMARD therapy is superior to MTX monotherapy for the treatment of PsA dactylitis.BMJ Publishing Group Ltd.Repositório da Universidade de LisboaVieira De Sousa, Elsa CristinaAlves, PedroRodrigues, Ana M.Teixeira, FilipaTavares Costa, JoséBernardo, AlexandraPimenta, SofiaPimentel-Santos, Fernando M.Gomes, João LagoasAguiar, RenataPinto, PatríciaVideira, TacianaCatita, CristinaSantos, HelenaBorges, JoanaSequeira, GraçaRibeiro, CéliaTeixeira, LídiaÁvila-Ribeiro, PedroMartins, Fernando M.Canhao, HelenaMcInnes, Iain B.Ribeiro, Ruy M.Fonseca, João Eurico2020-12-03T14:39:45Z20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/45110engAnn Rheum Dis 2020;79:490–4980003-496710.1136/annrheumdis-2019-2165001468-2060info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T16:46:37Zoai:repositorio.ul.pt:10451/45110Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:57:35.646348Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
GO-DACT : a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis |
title |
GO-DACT : a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis |
spellingShingle |
GO-DACT : a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis Vieira De Sousa, Elsa Cristina Anti-TNF Methotrexate Outcomes research Psoriatic arthritis |
title_short |
GO-DACT : a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis |
title_full |
GO-DACT : a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis |
title_fullStr |
GO-DACT : a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis |
title_full_unstemmed |
GO-DACT : a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis |
title_sort |
GO-DACT : a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis |
author |
Vieira De Sousa, Elsa Cristina |
author_facet |
Vieira De Sousa, Elsa Cristina Alves, Pedro Rodrigues, Ana M. Teixeira, Filipa Tavares Costa, José Bernardo, Alexandra Pimenta, Sofia Pimentel-Santos, Fernando M. Gomes, João Lagoas Aguiar, Renata Pinto, Patrícia Videira, Taciana Catita, Cristina Santos, Helena Borges, Joana Sequeira, Graça Ribeiro, Célia Teixeira, Lídia Ávila-Ribeiro, Pedro Martins, Fernando M. Canhao, Helena McInnes, Iain B. Ribeiro, Ruy M. Fonseca, João Eurico |
author_role |
author |
author2 |
Alves, Pedro Rodrigues, Ana M. Teixeira, Filipa Tavares Costa, José Bernardo, Alexandra Pimenta, Sofia Pimentel-Santos, Fernando M. Gomes, João Lagoas Aguiar, Renata Pinto, Patrícia Videira, Taciana Catita, Cristina Santos, Helena Borges, Joana Sequeira, Graça Ribeiro, Célia Teixeira, Lídia Ávila-Ribeiro, Pedro Martins, Fernando M. Canhao, Helena McInnes, Iain B. Ribeiro, Ruy M. Fonseca, João Eurico |
author2_role |
author author author author author author author author author author author author author author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
Repositório da Universidade de Lisboa |
dc.contributor.author.fl_str_mv |
Vieira De Sousa, Elsa Cristina Alves, Pedro Rodrigues, Ana M. Teixeira, Filipa Tavares Costa, José Bernardo, Alexandra Pimenta, Sofia Pimentel-Santos, Fernando M. Gomes, João Lagoas Aguiar, Renata Pinto, Patrícia Videira, Taciana Catita, Cristina Santos, Helena Borges, Joana Sequeira, Graça Ribeiro, Célia Teixeira, Lídia Ávila-Ribeiro, Pedro Martins, Fernando M. Canhao, Helena McInnes, Iain B. Ribeiro, Ruy M. Fonseca, João Eurico |
dc.subject.por.fl_str_mv |
Anti-TNF Methotrexate Outcomes research Psoriatic arthritis |
topic |
Anti-TNF Methotrexate Outcomes research Psoriatic arthritis |
description |
© author(s) (or their employer(s)) 2020. Re-use permitted under CC BY- nC. no commercial re-use. see rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-12-03T14:39:45Z 2020 2020-01-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10451/45110 |
url |
http://hdl.handle.net/10451/45110 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Ann Rheum Dis 2020;79:490–498 0003-4967 10.1136/annrheumdis-2019-216500 1468-2060 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
BMJ Publishing Group Ltd. |
publisher.none.fl_str_mv |
BMJ Publishing Group Ltd. |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799134519530356736 |